Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Silence Therapeutics
Biotech
Silence loses Mallinckrodt collab, wins in cardiovascular ph. 2
Silence Therapeutics used its full-year earnings results this morning to unveil a phase 2 win—but also the loss of one of its partnerships.
James Waldron
Mar 13, 2024 8:54am
Silence takes back 2 complement programs from Mallinckrodt
Mar 28, 2023 10:42am
Amgen will take heart drug into phase 3 to challenge Novartis
Nov 7, 2022 11:40am
FDA grants Silence's drug fast-track tag for a blood cancer
Sep 8, 2022 9:10am
Silence stops RNAi cancer trial over 'recruitment challenges'
Mar 17, 2022 9:00am
Silence says its drug lowers levels of heart disease risk factor
Feb 9, 2022 1:50pm